Pharmacokinetics, pharmacodynamics, and safety of single-dose sotrovimab in high-risk pediatric participants with mild to moderate COVID-19

Trial Identifier: 215226
Sponsor: GlaxoSmithKline
Collaborator:
Vir Biotechnology, Inc.
Start Date: December 2021
Primary Completion Date: June 2023
Study Completion Date: July 2023
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, AL Cullman, AL, United States, 35055-1921
United States, AZ Mesa, AZ, United States, 85210